CryoPort, Inc. - Common Stock (CYRX)

CryoPort (NASDAQ:CYRX) reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million. Chief Executive Officer Jerrell Shelton said revenue momentum continue

Cryoport (CYRX) Q1 2026 Earnings Transcript

Cryoport (CYRX) Q2 2025 Earnings Transcript

Cryoport (CYRX) Q1 2025 Earnings Transcript

Cryoport (CYRX) Q3 2025 Earnings Transcript

Cryoport (CYRX) Q4 2025 Earnings Call Transcript

Cryoport Inc (NASDAQ:CYRX) reports third-quarter financial results after the market close on Tuesday. Here's a rundown of the report.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Cryoport (NASDAQ: CYRX) announced launch of MVE Biological Solutions' new vapor shippers, offering improved safety and reliability for transporting sensitive biological materials at cryogenic temps. Stock closes lower by 4.83% at $7.290 on Monday.